Lupin launch tablets for treatment of Edema
Lupin announced the launch of Ethacrynic Acid Tablets USP, 25 mg used for the treatment of Edema. The pharma major had already received an approval from United States Food and Drug Administration (USFDA) earlier for this drug.
Ethacrynic Acid Tablets USP, 25 mg, is the generic equivalent of Edecrin Tablets, 25 mg, of Bausch Health Americas, Inc. It is used for curing Edema, associated with congestive heart failure, cirrhosis of the liver and renal disease, which includes nephrotic syndrome as well. Further, it can be used for the short-term management of ascites due to malignancy, idiopathic edema and lymphedema and also short-term management of hospitalised pediatric patients other than infants with congenital heart disease or the nephrotic syndrome. According to IQVIA MAT December 2019, Ethacrynic Acid Tablets USP had an annual sale of approximately USD 20 million in US.
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai in India. The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in various markets.
On Tuesday, the stock of the company closed at Rs 669.15, down by 0.61 per cent or Rs 4.10 per share. The 52-week high is Rs 882.15 and 52-week low is Rs 646.20 on BSE.